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Abstract
Objective
To assess over 3 years of follow-up the eﬀects of maintaining or switching to ocrelizumab (OCR) therapy on
clinical and MRI outcomes and safety measures in the open-label extension (OLE) phase of the pooled
OPERA: I/II studies in relapsing multiple sclerosis.

Methods
After 2 years of double-blind, controlled treatment, patients continued OCR (600 mg infusions every 24
weeks) or switched from interferon (IFN)-β-1a (44 μg 3 times weekly) to OCR when entering the OLE phase
(3 years). Adjusted annualized relapse rate, time to onset of 24-week conﬁrmed disability progression (CDP)/
improvement (CDP), brain MRI activity (gadolinium-enhanced and new/enlarging T2 lesions), and percentage brain volume change were analyzed.
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Results
Of patients entering the OLE phase, 88.6% completed year 5. The cumulative proportion with 24-week CDP
was lower in patients who initiated OCR earlier vs patients initially receiving IFN-β-1a (16.1% vs 21.3% at year
5; p = 0.014). Patients continuing OCR maintained and those switching from IFN-β-1a to OCR attained near
complete and sustained suppression of new brain MRI lesion activity from years 3–5. Over the OLE phase,
patients continuing OCR exhibited less whole brain volume loss from double-blind study baseline vs those
switching from IFN-β-1a (−1.87% vs −2.15% at year 5; p < 0.01). Adverse events were consistent with past
reports and no new safety signals emerged with prolonged treatment.

Conclusion
Compared with patients switching from IFN-β-1a, earlier and continuous OCR treatment up to 5 years
provided sustained beneﬁt on clinical and MRI measures of disease progression.

Classification of evidence
This study provides Class III evidence that earlier and continuous treatment with OCR provided sustained beneﬁt
on clinical and MRI outcomes of disease activity and progression compared with patients switching from IFNβ-1a. The study is rated Class III because of the initial treatment randomization disclosure that occurred after
inclusion in OLE.

Clinical trial identifiers
NCT01247324/NCT01412333.
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Glossary
AE = adverse event; ARR = annualized relapse rate; CDI = conﬁrmed disability improvement; CDP = conﬁrmed disability
progression; CI = conﬁdence interval; DBP = double-blind controlled treatment phase; DMT = disease-modifying therapy;
EDSS = Expanded Disability Status Scale; FSS = Functional Systems Score; Gd = gadolinium; GMV = gray matter volume;
HR = hazard ratio; IFN = interferon; Ig = immunoglobulin; ITT = intention-to-treat; LLN = lower limit of normal; MMRM =
mixed-eﬀect model of repeated measures; MS = multiple sclerosis; NEDA = no evidence of disease activity; OCR =
ocrelizumab; OLE = open-label extension; OPERA = A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif)
in Participants With Relapsing Multiple Sclerosis; PML = progressive multifocal leukoencephalopathy; RMS = relapsing
multiple sclerosis; UTI = urinary tract infection; WBV = whole brain volume; WMV = white matter volume.

Ocrelizumab (OCR) is a humanized monoclonal antibody
that selectively targets CD20+ B cells while preserving the
capacity for B-cell reconstitution and preexisting humoral
immunity.1,2 In phase III randomized, double-blind, doubledummy trials with identical designs (OPERA [A Study of
Ocrelizumab in Comparison With Interferon Beta-1a (Rebif)
in Participants With Relapsing Multiple Sclerosis] I
[NCT01247324] and OPERA II [NCT01412333]) in relapsing multiple sclerosis (RMS), OCR demonstrated superior eﬃcacy for preventing relapses and disability worsening,
and a higher rate of disability improvement, compared with
subcutaneous interferon (IFN)-β-1a given 3 times weekly.3
Signiﬁcant beneﬁts of OCR on MRI outcomes, including the
reduction of the number of gadolinium (Gd)-enhancing T1
lesions, new or newly enlarged hyperintense T2 lesions, new
hypointense T1 lesions, and brain volume loss (baseline to
week 96) were also reported.3 We report the interim eﬃcacy
and safety results of OCR over the 3-year follow-up in the
open-label extension (OLE) phase of phase III trials in patients with RMS (5 years of total follow-up).

Methods
Standard protocol approvals, registrations,
and patient consents
The relevant institutional review boards/ethics committees approved the trial protocols (NCT01247324 and NCT01412333).
All patients provided written informed consent.
Trial design and patients
As previously detailed,3 OPERA I (NCT01247324) and
OPERA II (NCT01412333) were phase III, multicenter,
randomized, double-blind, double-dummy, IFN-β-1a controlled trials with identical designs, of OCR in patients with
RMS (data available from Dryad, ﬁgure e-1, doi.org/10.5061/
dryad.stqjq2bzw). Key eligibility criteria included an age of
18–55 years, diagnosis of multiple sclerosis (MS; 2010 revised
McDonald criteria),4 and screening Expanded Disability
Status Scale (EDSS) score of 0–5.5. Consistency of baseline
characteristics and treatment eﬀects across both OPERA
studies met predetermined criteria for pooled eﬃcacy analysis, including annualized relapse rate (ARR) and conﬁrmed
disability progression (CDP).3 Following completion of the
double-blind controlled treatment phase (DBP) of both trials,
Neurology.org/N

patients meeting speciﬁc criteria (data available from Dryad,
supplemental data, doi.org/10.5061/dryad.stqjq2bzw) were
eligible to enter an OLE phase to evaluate the long-term
safety, tolerability, and eﬃcacy of OCR in RMS; patients who
declined or who were not eligible (since there was an OLE
screening phase) to participate in the OLE phase entered
safety follow-up. Patients entering the OLE phase ﬁrst entered
the OLE screening phase, which lasted up to 4 weeks. At the
start of the OLE phase, patients who received OCR in the
DBP continued OCR and patients from the IFN-β-1a group
were switched to OCR, given every 24 weeks; in order to
maintain blinding and in accordance with the start of the DBP,
all patients received the ﬁrst dose of OCR as 2 separate
300 mg infusions, 2 weeks apart. Patient treatment allocation
was unblinded after the last data point from the last patient
from the DBP was received. The 96-week core studies were
conducted between 2011 and 2015. The ﬁrst patient completing the DBP entered the OLE phase in August 2013; the
last ongoing patient entered the OLE phase in February 2015.
The clinical cutoﬀ date for inclusion of data in this analysis
was February 5, 2018. The OLE phase is planned until December 2020, with the collection of data for up to 8 years.
Classification of evidence
This study provides Class III evidence that earlier and continuous treatment with OCR provided sustained beneﬁt on
clinical and MRI outcomes of disease activity and progression
compared with patients switching from IFN-β-1a. The study is
rated Class III because of the initial treatment randomization
disclosure that occurred after inclusion in the OLE.
Efficacy assessments
The following endpoints, which were also measured during
the 96-week DBP, are reported for the OLE phase, using the
pooled OPERA trial population.
Annualized relapse rate

The ARR was calculated as the total number of protocoldeﬁned relapses (occurrence of new or worsening neurologic
symptoms [consistent with an increase of at least half a step
on the EDSS score, or 2 points on one of the appropriate
Functional Systems Scores (FSS), or 1 point on 2 or more of
the appropriate FSS] that were attributable to MS) for all
patients in the treatment group divided by the total patientyears of exposure to that treatment.
Neurology | Volume 95, Number 13 | September 29, 2020
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Twenty-four week confirmed disability
progression/improvement

CDP was deﬁned as an increase in the EDSS score from the
baseline of the DBP or of the OLE phase of at least 1.0 point
(increase of ≥0.5 points if baseline EDSS score >5.5); conﬁrmed
disability improvement (CDI) was deﬁned as a reduction in
EDSS score ≥1.0 point compared with baseline of the DBP or of
the OLE phase (reduction of ≥0.5 point if baseline EDSS score
>5.5). For analyses based on the OLE phase only, a rebaseline of
EDSS was performed for all patients, including those who had an
event of CDP/CDI during the DBP. All analyses from the DBP
baseline were based on the intention-to-treat (ITT) population,
except for CDI, which was performed in the prespeciﬁed subgroup of the ITT population with EDSS ≥2.0. All analyses from
OLE baseline were based on the OLE population with treatment
group assignment based on the originally randomized treatment,
except for CDI, which was performed in the prespeciﬁed subgroup of the OLE population with EDSS ≥2.0. For both CDP
and CDI, rebaselining at the start of OLE provides a representation of eﬃcacy during the OLE period unconfounded by any
disease activity during the DBP, hence values for the proportion
of patients with events during DBP and rebaselined OLE may not
correspond with those of the combined DBP and OLE period.
Mean change from baseline in EDSS score

Mean change from baseline in EDSS score was assessed at
scheduled visits during the DBP and the OLE phase.
Acute brain MRI lesion activity

The total number of new or newly enlarged T2 lesions and
total number of T1 Gd-enhancing lesions on brain MRI was
assessed every 48 weeks in the OLE phase.
Brain volume change

Percentage change in whole brain volume (WBV) was assessed
using SIENA/X.5 Percent change in cortical gray matter volume
(GMV) and white matter volume (WMV) was assessed using
paired Jacobian integration.6 All analyses from the DBP baseline
were based on the ITT population. All analyses from the OLE
baseline were based on the OLE population with treatment
group assignment based on the originally randomized treatment.
No evidence of disease activity (NEDA)

NEDA status was deﬁned as the combined absence of
protocol-deﬁned relapses, 24-week CDP, new or enlarging T2
lesions, and T1 Gd-enhancing lesions.
Safety
All patients who received any study treatment were included
in the safety population. All data collected during the DBP
and OLE and the safety follow-up were included in the safety
analyses. Safety outcomes are reported for the OLE phase
using the pooled OPERA I and OPERA II ITT population.
Statistical analyses
ARR was analyzed with the use of a generalized estimating
equation Poisson regression model in the ITT population.
e1856
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CDP/CDI at 24 weeks were assessed using Kaplan-Meier and
Cox survival analysis in the ITT population and for CDI, in
patients with a baseline EDSS score of ≥2.0; hazard ratios (HRs)
were estimated by stratiﬁed Cox regression. Mean change from
baseline in EDSS score was analyzed using the mixed-eﬀect
model of repeated measures (MMRM). The number of new T1
Gd-enhancing lesions and the number of new or enlarging T2
lesions were analyzed using a negative binomial model; in
previously reported analysis3 of lesion outcomes during the
DBP, results were adjusted for baseline T2 lesion volume,
baseline EDSS score (≤2.5 vs >2.5), and geographic region
(United States vs rest of the world). However, as patients had
no new T1 Gd-enhancing lesions/new or enlarging T2 lesions
at several time points, it was impossible to ﬁt a statistical model,
and unadjusted rates were adopted for the OLE instead. The
change in WBV, GMV, and WMV was analyzed using the
MMRM, adjusted for baseline WBV or GMV or WMV and
baseline EDSS score (<4.0 vs ≥4.0), study, and geographic region (United States vs rest of the world). NEDA was analyzed
using the Cochran-Mantel-Haenszel test stratiﬁed by study,
geographic region (United States vs rest of the world), and
baseline EDSS score (<4.0 vs ≥4.0) in a modiﬁed ITT population, which included all patients in the ITT population, but
patients who discontinued treatment early for reasons other
than lack of eﬃcacy or death and had NEDA before early discontinuation were excluded. Safety outcomes are reported as
incidence rates (events per 100 patient-years of exposure) with
Poisson distribution-based conﬁdence intervals (CIs).
Data availability
Qualiﬁed researchers may request access to individual patientlevel data through the clinical study data request platform
(vivli.org). Further details on Roche’s criteria for eligible studies
are available at vivli.org/members/ourmembers. For further
details on Roche’s Global Policy on the Sharing of Clinical
Information and how to request access to related clinical
study documents, see roche.com/research_and_development/
who_we_are_how_we_work/clinical_trials/our_commitment_
to_data_sharing.htm.

Results
Patient disposition, demographics, and
disease characteristics
Patient disposition and reasons for discontinuation are shown
in ﬁgure 1 by treatment group. More than 94% of patients in
both groups who completed the DBP entered the OLE phase.
Of 827 patients treated with OCR during the DBP, 702
(84.9%) entered the OLE phase and 623 (75.3%) remained at
year 5. Of the 829 patients treated with IFN-β-1a in the DBP,
623 (75.2%) entered the OLE phase and 551 (66.5%)
remained at year 5. Overall, 1,174 of 1,325 patients (89%)
who entered the OLE phase of the OPERA studies completed
year 5, representing 71% of the originally enrolled population
(n = 1,656). Patient demographics and disease characteristics
for the pooled studies at baseline of the DBP and at the start of
Neurology.org/N

Figure 1 Patient disposition in the pooled OPERA I and OPERA II intent-to-treat (ITT) population

Percentages in parentheses are of the ITT population. aClinical cutoff date: February 5, 2018; patients entering the open-label extension (OLE) phase who
completed the double-blind period (DBP): interferon (IFN)-β-1a 623/660 (94.4%) and ocrelizumab (OCR) 702/726 (96.7%). b88.4%, and c88.7%, of patients who
entered the OLE completed year 3. SFU = safety follow-up.

the OLE phase were well balanced between treatment arms and
between the ITT population and those patients with a baseline
EDSS score of ≥2.0 (table 1). The number of OCR doses
received (mean ± SD; median [range]) in the OLE phase
population was 7.3 ± 2.0, 8.0 (1–10) for continuous OCR
patients and 7.4 ± 1.9; 8.0 (1–10) in patients switching from
IFN-β-1a to OCR.
Clinical efficacy assessments
Patients receiving continuous OCR maintained a low ARR
through year 1 to year 5 (0.14, 0.13, 0.10, 0.08, and 0.07; ﬁgure
2). Switching from IFN-β-1a to OCR at the start of the OLE
phase was associated with a signiﬁcant reduction in ARR (0.20
in year 2 to 0.10 in year 3; adjusted rate ratio [95% CI] 2.069
[1.547–2.766], p < 0.001; 52% relative reduction), which was
maintained through years 4 and 5 (0.08 and 0.07; ﬁgure 2). In
the OLE phase, there was no diﬀerence in ARR at years 3, 4,
and 5 in patients receiving continuous OCR compared with
those switching from IFN-β-1a (p > 0.5, all comparisons;
ﬁgure 2).
Over the duration of the DBP and OLE periods, time point
analysis demonstrated that the proportion of patients with
24-week CDP from baseline remained signiﬁcantly lower in
patients receiving continuous OCR compared with those
switching from IFN-β-1a to OCR at the end of the DBP
(year 2: 7.7% vs 12.0%; p = 0.005), at the end of year 3
Neurology.org/N

(10.1% vs 15.6%; p = 0.002), at the end of year 4 (13.9% vs
18.1%; p = 0.03), and at the end of year 5 (16.1% vs 21.3%; p
= 0.014; ﬁgure 3A). The HR for patients receiving continuous OCR compared with those switching from IFN-β-1a to
OCR for time to ﬁrst 24-week CDP during the DBP was 0.60
(95% CI 0.43–0.84; p = 0.003); after rebaselining at the end
of the DBP (i.e., start of the OLE), the HR during the
OLE phase was 1.06 (95% CI 0.8–1.41; p = 0.7) (data
available from Dryad, ﬁgure e-2A, doi.org/10.5061/dryad.
stqjq2bzw).
The proportion of patients with 24-week CDI over the duration of the DBP and OLE periods (ﬁgure 3B) in patients
with a baseline EDSS score of ≥2.0 was numerically higher in
patients receiving continuous OCR compared with those
switching from IFN-β-1a to OCR at the end of the DBP (year
2: 16.8% vs 13.3%; p = 0.099), at the end of year 3 (20.6% vs
16.6%; p = 0.089), at the end of year 4 (23.7% vs 18.9%; p =
0.057), and at the end of year 5 (25.8% vs 20.6%; p = 0.046).
The HR for improvement (time to ﬁrst 24-week CDI) from
baseline to the end of the DBP in patients receiving continuous OCR compared with those switching from IFN-β-1a to
OCR was 1.31 (95% CI 0.96–1.78; p = 0.06; ﬁgure 3B); after
rebaselining at the end of the DBP (i.e., start of the OLE), the
HR during the OLE phase was 0.89 (95% CI 0.61–1.31; p =
0.6) (data available from Dryad, ﬁgure e-2B, doi.org/10.5061/
dryad.stqjq2bzw).
Neurology | Volume 95, Number 13 | September 29, 2020
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Table 1 Baseline demographics and disease characteristics for the pooled OPERA I and OPERA II populations at the start of the double-blind period (DBP) and open-label
extension (OLE)
DBP baseline

OLE baseline

DBP baseline EDSS score of ≥2.0

OLE baseline EDSS score of ≥2.0

IFN-β-1a 44 μg/OCR
600 mg (n = 829)

OCR 600 mg/OCR
600 mg (n = 827)

IFN-β-1a 44 μg/OCR
600 mg (n = 623)

OCR 600 mg/OCR
600 mg (n = 702)

IFN-β-1a 44 μg/OCR
600 mg (n = 614)

OCR 600 mg/OCR
600 mg (n = 628)

IFN-β-1a 44 μg/OCR
600 mg (n = 439)

OCR 600 mg/OCR
600 mg (n = 500)

Age, y, mean (SD)

37.2 (9.2)

37.1 (9.2)

39.3 (9.2)

39.2 (9.1)

38.6 (9.0)

38.3 (9.3)

41.0 (9.0)

40.4 (9.3)

Female, n (%)

552 (66.6)

541 (65.4)

408 (65.5)

454 (64.7)

406 (66.1)

408 (65.0)

297 (67.7)

326 (65.2)

EDSS, mean (SD)

2.8 (1.3)

2.6 (1.3)

3.3 (1.1)

3.3 (1.0)

3.4 (1.3)

3.1 (1.0)

2.8 (1.3)
d

2.7 (1.5)
e

Patients with T1 Gdenhancing lesions, n (%)a

327 (39.8)

Number of T1 Gd-enhancing
lesions, mean (SD)a

1.9 (5.0)d

1.8 (4.6)e

0.5 (2.1)e

Number of T1-hypointense
lesions, mean (SD)b

32.9 (35.1)d

32.4 (35.2)e

T2-hyperintense lesion
volume, cm3, mean (SD)c

10.2 (11.8)f

Number of T2 lesions, mean
(SD)b

51.0 (37.8)f

333 (40.7)

106 (17.3)

e

5 (0.7)

g

g

d

d

4 (0.8)l

233 (38.3)

256 (41.2)

77 (17.8)

0.02 (0.2)g

2.0 (5.3)g

1.8 (4.8)d

0.4 (1.4)d

0.02 (0.3)l

35.6 (36.8)h

33.9 (36.1)h

36.9 (36.8)g

36.5 (37.4)d

39.8 (38.0)h

37.8 (38.4)

10.8 (14.1)f

9.4 (11.5)i

10.1 (13.8)j

11.3 (12.4)k

12.2 (15.0)f

10.6 (12.0)m

11.6 (15.1)i

50.1 (38.8)f

55.5 (41.3)

50.9 (39.4)

53.9 (39.0)k

53.2 (39.8)f

59.3 (42.9)

53.2 (39.8)

Neurology.org/N

Abbreviations: EDSS = Expanded Disability Status Scale; Gd = gadolinium; IFN = interferon; OCR = ocrelizumab.
Demographics and disease characteristics at week 96 of the DBP (clinical cutoff dates: OPERA I, April 2, 2015; OPERA II, May 12, 2015) are considered baseline for the OLE phase.
For MRI measurements:
a
OLE baseline is the assessment at week 96.
b
OLE baseline is the sum of lesion counts at baseline, week 24, week 48, and week 96.
c
OLE baseline is the last assessment prior to or at the start of OLE treatment.
Patients missing and excluded for calculating percentages:
d
n = 7.
e
n = 9.
f
n = 5.
g
n = 6.
h
n = 1.
i
n = 33.
j
n = 44.
k
n = 4.
l
n = 3.
m
n = 28.

Figure 2 Annualized relapse rate (ARR) in double-blind controlled treatment phase (DBP) study years 1 and 2 and openlabel extension (OLE) years 1–3

Estimates are from analysis based on generalized estimating equation Poisson regression model with repeated measurements using unstructured covariance matrix, adjusted by randomized treatment, study, baseline Expanded Disability Status Scale (<4.0 vs ≥4.0), geographic region (United States vs rest of
the world), year, and treatment-by-year interaction. Log-transformed exposure time is included as an offset variable. aThe total number of relapses for all
patients in the treatment group divided by the total patient-years of exposure to that treatment. bDBP year 1 and DBP year 2 data include the intention-totreat population (number of patients available); year 3 (OLE year 1), year 4 (OLE year 2), and year 5 (OLE year 3) data include the OLE ITT population (number of
patients available). Clinical cutoff date: February 5, 2018. IFN = interferon; OCR = ocrelizumab.

Patients continuing OCR had a lower mean change from
baseline in EDSS score compared with patients switching
from IFN-β-1a to OCR, at the end of the DBP (year 2: −0.146
vs 0.032; p < 0.001), during year 3 (−0.118 vs 0.010; p =
0.008), during year 4 (−0.057 vs 0.041; p = 0.06), and during
year 5 (−0.043 vs 0.058; p = 0.07) (data available from Dryad,
ﬁgure e-3, doi.org/10.5061/dryad.stqjq2bzw).
MRI efficacy assessments
Patients receiving continuous OCR maintained the near
complete suppression of MRI disease activity seen in the DBP
through to year 5 (ﬁgure 4, A and B): the unadjusted rate of
total T1 Gd-enhancing lesions was 0.017 at the end of the DBP
(for year 2 only), 0.005 at year 3, 0.017 at year 4, and 0.006 at
year 5; and for new or newly enlarged T2 lesions, the unadjusted rate was 0.063 over year 2, 0.091 over year 3, 0.080
over year 4, and 0.031 over year 5. Patients switching from IFNβ-1a to OCR had almost complete and sustained suppression
of MRI lesion disease activity from year 3 to year 5 (ﬁgure 4, A
and B): the unadjusted rate of total T1 Gd-enhancing lesions
was 0.491 at the end of the DBP (year 2), decreasing to 0.007 at
year 3, 0.004 at year 4, and 0.004 at year 5; and for new or
enlarging T2 lesions, the unadjusted rate was 2.583 over the
duration of year 2, decreasing to 0.371 over year 3, 0.063 over
year 4, and 0.038 over year 5. In the OLE phase, there was no
diﬀerence in MRI lesion counts at years 3, 4, and 5 in patients
receiving continuous OCR compared with those switching
from IFN-β-1a (p > 0.5, all comparisons; ﬁgure 4), except for
new or enlarging T2 lesions at year 3, where the number was
lower in patients receiving continuous OCR compared with
those switching from IFN-β-1a (0.091 vs 0.371; p < 0.001;
ﬁgure 4B).
Neurology.org/N

At 5 years (OLE year 3), patients treated continuously with
OCR compared with those switching from IFN-β-1a to OCR
experienced signiﬁcantly lower brain atrophy measured by
change from DBP baseline in WBV, cortical GMV, and
WMV (adjusted rate: WBV –1.87% vs −2.15%, cortical
GMV −2.02% vs −2.25%, and WMV –1.33% vs −1.62%; p <
0.01 for all comparisons; ﬁgure 5, A1, B1, and C1). Similarly,
signiﬁcant diﬀerences between patients treated continuously
with OCR compared with patients switching from IFN-β-1a
to OCR were seen at years 2, 3, and 4 for change from
baseline in WBV, cortical GMV, and WMV (adjusted rates: p
≤ 0.01 for all comparisons; ﬁgure 5, A1, B1, and C1), except
for cortical GMV at year 3, where no diﬀerence was found
(adjusted rate −1.47% vs −1.56%; p = 0.155; ﬁgure 5B1).
When expressed as annualized percent change in volume
occurring during the preceding 48 weeks, the adjusted rates
were generally stable during the OLE phase for patients
switching from IFN-β-1a to OCR and those continuing
OCR (ﬁgure 5, A2, B2, and C2).
NEDA in the OLE
In patients treated with OCR compared with IFN-β-1a, the
relative proportion of patients with NEDA was increased by
74% in the DBP (OCR 48.5% [n = 369/761] vs IFN-β-1a
27.8% [n = 210/756]; p < 0.001) and by 88% over the duration of the DBP and OLE periods (OCR 35.7% [n = 255/
715] vs IFN-β-1a/OCR 19.0% [n = 140/738]; p < 0.001).
During the OLE period alone, the proportion of patients with
NEDA was 65.4% (n = 409/625) in patients treated continuously with OCR compared with 55.1% (n = 310/563) in
those switching from IFN-β-1a to OCR, a relative diﬀerence of
19% (p < 0.001).
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Figure 3 Time to onset of confirmed disability progression (CDP) and confirmed disability improvement (CDI) for at least 24
weeks during double-blind controlled treatment phase (DBP) and open-label extension (OLE) periods

Time to onset of (A) CDP and (B) CDI. Curves show Kaplan-Meier estimates of the proportion of patients with disability progression/improvement events
relative to the original double-blind treatment period baseline throughout double-blind and OLE periods. Without imputation. Intention-to-treat (ITT)
population. Pooled OPERA I and OPERA II population; DBP clinical cutoff dates: April 2, 2015, and May 12, 2015, respectively; OLE clinical cutoff date: February
5, 2018. Data shown up to week 240, the last visit all ongoing patients completed. HR = hazard ratio; IFN = interferon; OCR = ocrelizumab.

Safety in the OLE
Table 2 summarizes the safety analyses in all patients treated
with OCR over a period of 5 years, which includes patients
treated continuously with OCR (5 years) and patients switched
from IFN-β-1a (3 years). As of February 2018, 1,448 patients
with MS received OCR during the DBP and associated OLE
periods of the OPERA trials. The rate of adverse events (AEs)
in the overall OCR exposure population was 220 (95% CI
217–224) per 100 patient-years, lower than the rate observed at
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the primary DBP analysis cutoﬀ date (May 2015) for each
group (events per 100 patient-years [95% CI], IFN-β-1a: 296
[287–305]; OCR 290 [281–299]). The most common AEs
included infusion-related reactions, urinary tract infections
(UTIs), and upper respiratory tract infections. Overall, the rate
of serious AEs was 6.1 (95% CI 5.5–6.8) events per 100 patientyears, consistent with the rate observed at the primary analysis
cutoﬀ date for each group (IFN-β-1a: 6.29 [5.05–7.75]; OCR:
5.39 [4.26–6.72]). The rate of infections per 100 patient-years
Neurology.org/N

Figure 4 Total number of T1 gadolinium (Gd)-enhancing lesions and new or enlarging T2 lesions in the double-blind
controlled treatment phase (DBP) and open-label extension (OLE)

(A) T1 Gd-enhancing lesions and (B) new or enlarging T2 lesions in the DBP and OLE. aDBP week 24, DBP year 1, and DBP year 2 data include the intention-totreat (ITT) population; year 3 (OLE year 1), year 4 (OLE year 2), and year 5 (OLE year 3) data include the OLE ITT population; clinical cutoff date: February 5, 2018.
b
Unadjusted rate. IFN = interferon; OCR = ocrelizumab.

was 75.3 (95% CI 73.1–77.6), consistent with the rate observed
at the primary analysis cutoﬀ date for each group (IFN-β-1a:
67.8 [95% CI 63.5–72.2]; OCR: 84.5 [95% CI 79.9–89.4]).
The most common serious AEs were classiﬁed as infections,
which occurred at a rate of 1.5 per 100 patient-years (95% CI
1.2–1.8) over the 5-year period, and this was similar to the rate
observed at the primary analysis cutoﬀ date (IFN-β-1a: 1.79
[1.16–2.64]; OCR: 0.83 [0.43–1.45]). The most common
serious infections were UTIs and pneumonia. Two potential
serious opportunistic infections were reported in the OLE
period; both patients recovered with treatment by standard
therapies (systemic Pasteurella infection in a patient with
RMS following a cat bite; enterovirus-induced fulminant
hepatitis in a diabetic patient with RMS, resulting in liver
transplant). As of end of April 2019, no cases of progressive
multifocal leukoencephalopathy (PML) were identiﬁed in the
overall OCR exposure population for the pooled OPERA
studies. The crude incidence rate of all malignancies per 100
patient-years in the overall OCR exposure population was
0.40 (0.26–0.61), and at the primary analysis cutoﬀ date the
Neurology.org/N

incidence rate for IFN-β-1a was 0.14 (0.02–0.52) and for
OCR was 0.28 (0.08–0.71). A list of malignancies from the
DBP and OLE phase of the pooled OPERA studies as of
February 2018 is provided in the supplemental data (available
from Dryad, supplemental data, doi.org/10.5061/dryad.
stqjq2bzw).
The rate per 100 patient-years of AEs leading to treatment
withdrawals in the overall OCR exposure population (year 5:
1.36 [95% CI 1.08–1.70]) did not increase over time (rate
observed at the primary analysis cutoﬀ date: IFN-β-1a: 3.93
[2.96–5.12]; OCR: 2.35 [1.63–3.28]).
Over 5 study years in the pooled OPERA study population, a
reduction in serum immunoglobulin (Ig) levels was observed.
At baseline, the number (%) of patients with Ig concentrations below the lower limit of normal (LLN) were 7 (0.5%)
for IgG, 17 (1.2%) for IgA, and 7 (0.5%) for IgM. Over 5 study
years, for the majority of patients, Ig levels remained above the
LLN (data available from Dryad, table e-1, doi.org/10.5061/
dryad.stqjq2bzw); the number (%) of patients with a decrease
Neurology | Volume 95, Number 13 | September 29, 2020
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Figure 5 Percentage change from baseline and annualized, in whole brain volume (WBV), cortical gray matter volume
(CGMV), and white matter volume (WMV) in the double-blind controlled treatment phase (DBP) and open-label
extension (OLE)

Percentage change (A.a, B.a, C.a) from baseline and (A.b, B.b, C.b) annualized, in (A) WBV, (B) CGMV, and (C) WMV in the DBP and OLE mixed-effect model of
repeated measures (MMRM) plot, intention-to-treat (ITT) population. Pooled OPERA [Rebif] I and OPERA II (clinical cutoff date: February 5, 2018); p values
shown for difference in adjusted means. Graph includes patients with assessment at baseline and at least 1 postbaseline value. Estimates are from analysis
based on MMRM using unstructured covariance matrix: percentage change = baseline brain volume + geographic region (United States vs rest of the world) +
baseline Expanded Disability Status Scale (<4.0 vs ≥4.0) + study + week + treatment + treatment × week (repeated values over week) + baseline brain volume ×
week. aThe bars represent the annualized change in WBV, CGMV, or WMV occurring during the time period delineated by the axis label and the preceding 24
or 48 weeks. BL = baseline; CI = confidence interval; IFN = interferon; OCR = ocrelizumab.

e1862

Neurology | Volume 95, Number 13 | September 29, 2020

Neurology.org/N

Table 2 Adverse events, serious adverse events, and adverse events leading to discontinuation during the double-blind
period (DBP) and open-label extension (OLE) phase of the pooled OPERA I and OPERA II populations
OPERA (pooled) controlled treatment perioda
Event

IFN-β-1a rate per 100
patient-years (95% CI)c

OCR rate per 100
patient-years (95% CI)c

OPERA DBP/OLE,b OCR rate
per 100 patient-years (95% CI)c

Any adverse eventd

296 (287–305)

290 (281–299)

220 (217–224)

Adverse events leading to study
treatment discontinuation

3.93 (2.96–5.12)

2.35 (1.63–3.28)

1.36 (1.08–1.70)

Infections and infestationsd

67.8 (63.5–72.2)

84.5 (79.9–89.4)

75.3 (73.1–77.6)

Urinary tract infection

9.7 (8.1–11.4)

11.6 (9.9–13.5)

11.7 (10.8–12.6)

Nasopharyngitis

8.3 (6.9–9.9)

13.0 (11.2–15.0)

11.0 (10.2–11.9)

Upper respiratory tract infection

9.4 (7.8–11.1)

13.3 (11.5–15.3)

12.6 (11.7–13.6)

Bronchitis

2.2 (1.5–3.1)

3.5 (2.6–4.6)

3.7 (3.2–4.2)

Influenza

3.3 (2.4–4.4)

3.1 (2.3–4.2)

2.7 (2.3–3.1)

17.1 (15.0–19.4)

45.9 (42.4–49.5)

28.2 (26.8–29.6)

7.9 (6.5–9.5)

34.9 (31.9–38.1)

18.2 (17.1–19.3)

34.8 (31.8–38.0)

31.6 (28.8–34.7)

20.7 (19.5–21.9)

12.4 (10.6–14.4)

9.5 (8.0–11.3)

4.7 (4.2–5.3)

25.0 (22.5–27.8)

24.3 (21.8–27.0)

18.8 (17.6–20.0)

Back pain

3.1 (2.2–4.1)

4.1 (3.1–5.3)

3.0 (2.6–3.5)

Arthralgia

3.9 (3.0–5.1)

3.5 (2.6–4.6)

2.8 (2.3–3.2)

Pain in extremity

2.9 (2.1–4.0)

3.7 (2.7–4.8)

2.3 (1.9–2.8)

51.3 (47.6–55.2)

17.3 (15.2–19.5)

10.6 (9.8–11.5)

5.7 (4.5–7.1)

5.4 (4.3–6.7)

3.5 (3.1–4.0)

14.2 (12.3–16.3)

14.4 (12.5–16.5)

8.5 (7.7–9.2)

4.2 (3.2–5.4)

4.9 (3.8–6.2)

2.9 (2.5–3.4)

0.14 (0.02–0.52)

0.28 (0.08–0.71)

0.40 (0.26–0.61)

6.29 (5.05–7.75)

5.39 (4.26–6.72)

6.1 (5.5–6.8)

Serious infections

1.79 (1.16–2.64)

0.83 (0.43–1.45)

1.5 (1.2–1.8)

Number of potential serious OIsh

0

0

2

0.14 (0.02–0.52)

0.07 (0–0.38)

0.04 (0–0.13)

Injury, poisoning and procedural
complicationsd
Infusion-related reactions
Nervous system disordersd
Headache
Musculoskeletal and connective
tissue disordersd

General disorders and administration
site conditionsd
Fatigue
Psychiatric disorders

d

Depression
Malignanciesd,e,f
Serious adverse events

d

g

Fatalitiesi

Abbreviations: CCOD = clinical cutoff date; CI = confidence interval; IFN = interferon; MedDRA = Medical Dictionary for Regulatory Activities; OCR = ocrelizumab; OI = opportunistic infection.
a
Includes patients who received IFN-β-1a during the controlled treatment period of the OPERA I (CCOD April 2015) and OPERA II (CCOD May 2015) studies.
b
Includes patients who received any dose of OCR during the controlled treatment and associated OLE phase of the OPERA I and OPERA II studies; data from
patients who were originally randomized to comparator (IFN-β-1a) are included after the switch to open-label OCR treatment. CCOD for inclusion of data in
this analysis was February 5, 2018.
c
Multiple occurrences of the same adverse event (except for malignancies) in one patient are counted multiple times.
d
Includes adverse events falling into the MedDRA versions 18.0 (OPERA [pooled] controlled treatment period) and 20.1 (CCOD: February 2018).
e
Malignancies are identified using adverse events falling into the standard MedDRA query “Malignant tumours (narrow).”
f
Reported as incidence rate per 100 patient-years of first malignancy.
g
Serious infections are defined using adverse events falling into the MedDRA system organ class Infections and Infestations, and using “Is the event
nonserious or serious?” from the adverse event case report form.
h
Potential serious OIs were medically reviewed.
i
A causal association between OCR and fatal events could not be established.
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below the LLN at year 5 were 33 (5.4%) for IgG, 31 (5.1%)
for IgA, and 164 (29.5%) for IgM.

Discussion
These interim results from the OPERA extension study provide
several important insights on the eﬃcacy and safety of longterm (up to 5 years) treatment with OCR in patients with
RMS. The low levels of disease activity observed in patients
treated with OCR during the 2-year controlled period3 were
sustained from years 3–5, suggesting a beneﬁt of earlier treatment and persistence of the eﬀect with maintained therapy. In
patients who switched from IFN-β-1a, OCR consistently led to
a rapid decrease in relapse activity and an almost complete
suppression of MRI activity. Disability accrual occurred at
similarly low rates in the 2 groups during the OLE phase but, at
the end of year 5, the proportion of patients with CDP from
baseline of the DBP was lower in those originally treated with
OCR. The safety proﬁle observed in years 3–5 was generally
consistent with that observed during the controlled period,
with no additional safety ﬁndings that suggest potential deleterious eﬀects of long-term exposure to OCR.
In patients treated early and continuously with OCR, consistent
and persistent eﬀects were evident on clinical and MRI measures of inﬂammatory disease activity. ARR remained low over 5
years. Consistent with the eﬀects on relapses, the near complete
suppression of subclinical disease activity, as measured by MRI,
observed in the DBP was maintained throughout the OLE
phase, with few patients exhibiting either T1 Gd-enhancing
lesions (0.006 lesions per scan) or new/enlarging T2 lesions
(0.031 lesions per scan) at the end of year 5. Patients who
started OCR after switching from IFN-β-1a experienced signiﬁcant decreases in levels of disease activity, with relapse rates
and lesion counts becoming similar to those observed in patients on early and continuous OCR at year 3 and consistently
maintained through to year 5. The eﬀect of OCR in reducing
the relapse rate is of particular relevance to the long-term
prognosis, as natural history and long-term follow-up studies of
MS disease-modifying therapies (DMTs) show that more frequent relapses early in the disease course, and relapses occurring
over the 2- to 3-year interval of a randomized clinical trial, are
associated with adverse long-term disability outcomes.7
The beneﬁts of earlier and sustained OCR treatment for
measures of disease progression were evidenced by lower levels
of clinically evaluated CDP, with only 16.1% of patients who
continued OCR experiencing 24-week CDP at the end of the
OLE phase (year 5). In patients who switched from IFN-β-1a, a
treatment eﬀect of OCR was observed starting in the ﬁrst year
of the OLE, leading to rates of disability progression similar to
those seen in patients continuing OCR in the OLE phase.
However, a higher proportion of IFN-β-1a–treated patients
experienced 24-week CDP by the end of the OLE phase (year
5). Those patients who initiated OCR 2 years earlier accrued
signiﬁcantly less disability progression compared with those
e1864
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switched from IFN-β-1a (16.1% vs 21.3%). Similarly, by the
end of the OLE phase (year 5), a signiﬁcantly higher proportion of patients initiating OCR 2 years earlier achieved
improvements in disability compared with patients switching
from IFN-β-1a (25.8% vs 20.6%). These results add to the body
of evidence that early high-eﬃcacy treatment is more favorable
than the traditional escalation approach. A recent observational
study demonstrated that patients commencing high-eﬃcacy
DMTs, including OCR, early after disease onset accumulate
less long-term disability compared with those exposed later in
their disease.8–11
OCR also slowed the rate of brain volume loss. At 5 years from
DBP baseline, patients on early and continuous OCR experienced lower WBV loss during the DBP compared with IFNβ-1a, and the diﬀerence between the 2 groups was maintained
throughout the OLE phase. The beneﬁcial eﬀect was also observed in both the white matter and cortical gray matter
compartments, with the exception of cortical GMV at year 3
where the absence of a diﬀerence might be due to the reversal
of pseudoatrophy aﬀecting gray matter in patients switching
from IFN-β-1a to OCR.12 In patients with MS, a parenchymal
loss of ≥0.4% per year (≥2.0% over a 5-year period) has been
proposed as a pathologic atrophy rate.13 The 5-year cumulative
WBV loss from DBP baseline in patients treated early and
continuously with OCR (−1.87%) was lower than in those that
switched from IFN-β-1a (−2.15%). Taken together, our ﬁndings converge in demonstrating that patients with RMS who
start later with high-eﬃcacy treatment do not catch up on
clinical and MRI outcomes reﬂecting residual functional loss
and tissue damage.
The durable eﬃcacy of OCR across multiple endpoints, with an
early impact not only on clinical and MRI measures of inﬂammation but also on disease progression, was accompanied
by a safety proﬁle consistent with previous reports.3 This was
reﬂected in the low on-study attrition rates, where almost 90%
of all patients who entered the OLE phase completed year 5,
indicating that OCR was generally well-tolerated. The reported
rates of AEs per 100 patient-years with OCR during the OLE
out to year 5 continue to be generally consistent with those
seen during the DBP in patients with RMS. Consistent with
results of previously reported trials,3,14 the incidence rates of
malignancies in patients treated with OCR remain within the
range of placebo data from clinical trials in MS and epidemiologic data for this patient population.14,15 A small increase in
serious infections has been previously reported during OLE
observations in patients with primary progressive MS treated
with OCR.16 No cases of PML occurred in the controlled
treatment period of the OCR MS clinical trials (pivotal phase
III studies and the phase II study) and to date, no cases have
been observed in the ongoing OLE of these studies or in the
other ongoing MS clinical trials. Outside of clinical trials, as of
October 2019, there have been 8 conﬁrmed cases of PML in
patients with MS treated with OCR: 7 cases of probable carryover PML (6 switching from natalizumab, 1 from ﬁngolimod); in one case, the patient had not been treated with other
Neurology.org/N

DMTs but had contributing risk factors for PML, including old
age (78 years) and preexisting grade 1 lymphopenia (which
worsened to grade 2 during treatment). No other PML cases
with OCR have been reported to date (based on drug product
sales as of October 2019, where an estimated 130,000 patients
with RMS and PPMS have received OCR treatment for approximately 140,000 patient-years).16 The observed decrease
in Ig levels and potential implications for patient safety, such as
serious infections, need to be considered in the context of
longer follow-up data.
As with other extension studies of DMTs, deﬁnitive conclusions related to eﬃcacy outcomes are limited by the absence of a control arm, and the inﬂuence of regression to the
mean, which has been described in MS studies, cannot be
excluded.17 As blinding was not maintained in the OLE
phase, some rater assessment bias could have been introduced, although EDSS raters continue to be blinded to all
other procedures, and MRI interpretation remains masked
in the OLE phase. There is a possibility of selection bias
given that participation in the extension was voluntary.
However, this is unlikely to be signiﬁcant as over 94% of
patients in both groups who completed the DBP entered the
OLE, with 88% of these patients completing year 5. It should
also be noted that the disease duration at baseline for the
majority of the patients enrolled in the OPERA I/II studies
was longer than the 5 years deﬁned in one study as the
threshold for early MS,9 but the duration was typical of other
clinical trials in the higher-eﬃcacy DMT era. The long-term
outcome of ocrelizumab therapy in patient populations with
earlier MS disease course requires further study.
Studies that demonstrate the maintenance of long-term eﬃcacy
and safety of DMTs are valuable since patients with MS need to
receive DMTs over the long term. The results of this analysis of
5-year data from the DBP and OLE of the pooled OPERA
studies underscore persistence of the OCR treatment eﬀect and
suggest that early and continuous treatment provides sustained
long-term beneﬁt. These and other data support the early use of
highly eﬀective therapies that impact clinical and MRI measures
of disease activity and progression in RMS to optimize shortand long-term patient outcomes.18
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